UNSPSC 51314303: Carbinoxamine/gauifenesin/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314303 Carbinoxamine/guaifenesin/pseudoephedrine is a Commodity code that in recent state and local procurement appears to span a broader pharmaceutical and over-the-counter product supply category than its specific drug-name designation suggests. State and local governments soliciting under this code are seeking manufacturers and distributors of generic pharmaceuticals, OTC products, and emergency-response medications such as naloxone. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The work involves supplying products through authorized wholesalers, meeting FDA and Drug Supply Chain Security Act compliance, maintaining cGMP certification, and fulfilling quarterly or ongoing delivery schedules to public health facilities and participating government jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; vendors must provide unit costs and comply with E-Verify and drug-free workplace requirements, with potential FEMA funding. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for a Therapeutic Pharmacy Initiative, seeking vendor capabilities for self-insured health plans and state agencies outside traditional PBM and GPO channels. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon; vendors must work with three authorized wholesalers and submit NDC-specific pricing with 75 percent evaluation weight on price competitiveness, 10 percent on fixed pricing structure, and 5 percent each on administrative compliance, EDI capability, and administrative fee agreement.